Drugs / RAD301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05799274 | Nov 2023 → Aug 2026 overdue | cervical cancer, endometrial cancer, esophageal squamous cell carcinoma, non-small cell lung carcinoma +2 | Radiopharm Theranostics, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-03-14 | Radiopharm Theranostics, Ltd | Results Initiation Research Report Radiopharm (ASX:RAD) Near to market imaging drug radiopharmtheranostics.com ↗
The trial s howed that Pivalate can be used to detect and monitor cerebral metastases. |
| 2022-12-30 | Radiopharm Theranostics, Ltd | Regulatory aVb6 Integrin (RAD301) IND approval for Phase 1 trial radiopharmtheranostics.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-14 | Radiopharm Theranostics, Ltd | Initiation Research Report Radiopharm (ASX:RAD) Near to market imaging drug radiopharmtheranostics.com ↗ |
| 2024-03-06 | Radiopharm Theranostics, Ltd | Multiple RAD301 data releases to be presented at EMIM radiopharmtheranostics.com ↗ |
| 2023-12-18 | Radiopharm Theranostics, Ltd | RAD’s 68Ga-Trivehexin (RAD301) featured in prestigious peer-reviewed journal RSC Medicinal Chemistry radiopharmtheranostics.com ↗ |
| 2022-12-30 | Radiopharm Theranostics, Ltd | aVb6 Integrin (RAD301) IND approval for Phase 1 trial radiopharmtheranostics.com ↗ |
| 2022-09-27 | Radiopharm Theranostics, Ltd | Ga68-Integrin (RAD301) selected for presentation at EANM radiopharmtheranostics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAD301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05799274 ↗ |
| Known as | [68Ga]-RAD301 | “RAD301 ([68Ga]-RAD301)” NCT05799274 ↗ |
| Route | Intravenous | “intravenous (IV) administration” NCT05799274 ↗ |